Given that the basic inflammatory pathogenesis of CRSwNP has been classified as a Type-2 inflammatory disease, driven by the key cytokines IL-4, IL-5, and IL-13, and IgE antibody, biological treatments with monoclonal antibodies have been introduced as an optional treatment for patients with poor disease control [5]. Here, IL13 is linked to chronic rhinosinusitis with nasal polyps.